Pharmaceuticals company Strides Pharma Science announced Q1FY25 results: Revenues at Rs 10,875 million, Grew 16.7% YoY in line with FY25 Outlook Gross Margin improved by 264 bps YoY to 61.3% EBITDA grew by 28.7% YoY to Rs 2,170 million with EBITDA margin at 20%, a growth of 187 bps YoY US revenues at a historic high of USD 70 million in Q1FY25, a growth of 24.5% YoY Q1FY25 Adjusted PAT at Rs 839 million and Reported PAT at Rs 683 million Reported EPS at Rs 7.6 and Adj EPS at Rs 9.1 for Q1FY25 Arun Kumar, Founder & Executive Chairperson, and Badree Komandur, MD & Group CEO, commented on the performance and said, “Our emphasis on profitability, efficiency and growth has led to a strong performance across markets, allowing us to deliver superior returns ahead of the projected timelines for our FY25 outlook. The company achieved critical thresholds of 20% EBITDA margin, Rs 683m of reported PAT and 2.3x Debt/EBITDA ratio. We are confident of sustaining the momentum with continuous improvement in the quality of business. The company has increased its focus on digitization, automation, and ESG for better compliance and business outcomes.” Result PDF
Pharmaceuticals company Strides Pharma Science announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Highest ever quarterly Revenue of Rs 10,583 million Gross Margin returned to a historic high of 60.7% in Q4FY24 Highest ever quarterly EBITDA of Rs 2,040 million FY24 Financial Highlights: Highest ever full-year Revenue of Rs 40,555 million in FY24, up 14.4% YoY Highest ever full-year EBITDA of Rs 7,477 million in FY24, up 77.6% YoY US business achieved top end of USD 250 million revenue outlook for FY24, grew by 11.8% YoY Net Debt reduced by Rs 3,131 million in FY24 Net Debt to EBITDA improved to 2.72x in FY24 Arun Kumar, Founder, Executive Chairperson & Managing Director, commented on the performance and said, “FY24 was an exceptional year for Strides, marked by the successful completion of our Reset strategy initiated in FY22. The company achieved all its key objectives laid down in our Reset strategy and has bounced back to become a strong and resilient company. As a result of our focus on consistent growth and cost containment, FY24 concluded as the best year in the Company’s history in terms of both Revenue and absolute EBITDA. With today’s leadership announcement, we have introduced a well-structured succession and leadership development program, guided by the Board. I am confident that the strong internal talent we have developed over the years will ensure the company's continued long-term growth. In the near term, we will continue to focus on operating cash flows while investing in growth to ensure that the efforts of our Reset are balanced by an improved revenue CAGR, in the coming years. Our ESG efforts have started to yield results, with our EcoVadis rating improving from 30 to 44 during the first year of review. We will continue to intensify our efforts to become a more sustainable and responsible company”. Result PDF